Novartis continues to cut jobs in Switzerland
Article excerpt
Highlighted: the sentence this signal was extracted from
Novartis announced on September 2 that it would cease the production of biologics in Kleinbasel by the end of 2027. Part of the activities is to be moved to the Novartis Campus in Basel, and the majority of production will be relocated abroad in the future. For Syna, it is clear: The reduction of production capacities and jobs in Switzerland must not simply be accepted. "Enough with expanding profit margins, we need pharmaceutical production in Switzerland," says Astrid Beigel, Head of Industry at Syna.
